Cargando…
Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma
In mammalian cells, microtubules are present both in interphase and dividing cells. In the latter, microtubules forming the mitotic spindle are highly dynamic and exquisitely sensitive to therapeutic inhibitors. Developed to alter microtubule function, microtubule-binding agents have been proven to...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3999274/ https://www.ncbi.nlm.nih.gov/pubmed/24790457 http://dx.doi.org/10.2147/OTT.S46019 |
_version_ | 1782313479920680960 |
---|---|
author | Loong, Herbert H Yeo, Winnie |
author_facet | Loong, Herbert H Yeo, Winnie |
author_sort | Loong, Herbert H |
collection | PubMed |
description | In mammalian cells, microtubules are present both in interphase and dividing cells. In the latter, microtubules forming the mitotic spindle are highly dynamic and exquisitely sensitive to therapeutic inhibitors. Developed to alter microtubule function, microtubule-binding agents have been proven to be highly active as an anticancer treatment. Significant development of microtubule-binding agents has taken place in recent years, with newer anti-tubulin agents now showing novel properties of enhanced tumor specificity, reduced neurotoxicity, and insensitivity to chemoresistance mechanisms. Hepatocellular carcinoma remains one of the most difficult cancers to treat, with chemotherapies being relatively ineffective. There is now evidence to suggest that microtubule-binding agents may be effective in the treatment of hepatocellular carcinoma, especially when used in combination with mammalian target of rapamycin inhibitors. Preclinical models have suggested that the latter may be able to overcome resistance to microtubule binding agents. In this review article, recent developments of novel microtubule binding agents and their relevance to the treatment of hepatocellular carcinoma will be discussed. |
format | Online Article Text |
id | pubmed-3999274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-39992742014-04-30 Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma Loong, Herbert H Yeo, Winnie Onco Targets Ther Review In mammalian cells, microtubules are present both in interphase and dividing cells. In the latter, microtubules forming the mitotic spindle are highly dynamic and exquisitely sensitive to therapeutic inhibitors. Developed to alter microtubule function, microtubule-binding agents have been proven to be highly active as an anticancer treatment. Significant development of microtubule-binding agents has taken place in recent years, with newer anti-tubulin agents now showing novel properties of enhanced tumor specificity, reduced neurotoxicity, and insensitivity to chemoresistance mechanisms. Hepatocellular carcinoma remains one of the most difficult cancers to treat, with chemotherapies being relatively ineffective. There is now evidence to suggest that microtubule-binding agents may be effective in the treatment of hepatocellular carcinoma, especially when used in combination with mammalian target of rapamycin inhibitors. Preclinical models have suggested that the latter may be able to overcome resistance to microtubule binding agents. In this review article, recent developments of novel microtubule binding agents and their relevance to the treatment of hepatocellular carcinoma will be discussed. Dove Medical Press 2014-04-16 /pmc/articles/PMC3999274/ /pubmed/24790457 http://dx.doi.org/10.2147/OTT.S46019 Text en © 2014 Loong and Yeo. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Loong, Herbert H Yeo, Winnie Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma |
title | Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma |
title_full | Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma |
title_fullStr | Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma |
title_full_unstemmed | Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma |
title_short | Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma |
title_sort | microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3999274/ https://www.ncbi.nlm.nih.gov/pubmed/24790457 http://dx.doi.org/10.2147/OTT.S46019 |
work_keys_str_mv | AT loongherberth microtubuletargetingagentsinoncologyandtherapeuticpotentialinhepatocellularcarcinoma AT yeowinnie microtubuletargetingagentsinoncologyandtherapeuticpotentialinhepatocellularcarcinoma |